Mechanism of Action: Key Advances in Hematology Oncology
BRAF Inhibition: Halting Cancer Cell GrowthCancers develop when mutations in critical genes alter cells’ ability to proliferate, differentiate, and die. One of these critical genes is the BRAF gene. Mutations in BRAF result in overactive, or oncogenic, BRAF protein, which ultimately enhances cell proliferation and survival.1 Because BRAF mutations are present in more than half of melanomas—the deadliest form of skin cancer—and to a lesser degree in other solid tumors,2 oncogenic BRAF has become a crucial target of small-molecule drug discovery efforts.3 Since 2011, 3 kinase inhibitors have been approved for use in patients with BRAF mutation–positive unresectable or metastatic melanoma as detected by a US Food and Drug Administration (FDA)-approved test.4-6 At least 4 BRAF inhibitors are in clinical development for melanoma, papillary thyroid cancer, colorectal cancer, ovarian cancer, non-small cell lung cancer, and other solid tumors.7 What does BRAF do in normal cells? RAF kinases are a component of the RAS-RAF pathway,8 serving as intermediaries in extracellular signaling from cell surface receptors.1 BRAF, one member of the RAF family of serine/threonine protein kinases, is encoded by the BRAF gene.1,2 BRAF plays an important role as an intermediary in RAS-RAF signaling and, ultimately, in cell proliferation and survival.8-10 In normal cells, extracellular signaling through the RAS-RAF pathway starts with growth factors that bind to and activate receptor tyrosine kinases on the cell surface. This, in turn, activates a signaling cascade that includes mitogen-activated protein kinase kinase (MAPKK, also known as MEK) and extracellular signalregulated kinase (ERK), as seen in the Figure. Specific steps are involved in this cell signaling cascade8-10:
- Growth factors in the extracellular space activate receptor tyrosine kinases
- Receptor tyrosine kinases initiate RAS-RAF signaling
- Activation of RAS activates RAF proteins, including BRAF
- Activation of RAF leads to MEK phosphorylation
- MEK then phosphorylates ERK, which directly and indirectly activates various gene transcription factors
- Gene transcription factors direct the expression of specific genes that govern cell proliferation and survival.
VemurafenibVemurafenib (Zelboraf), the first commercialized BRAF inhibitor, was approved by the FDA in August 2011 for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test. The cobas 4800 BRAF V600 Mutation Test, a DNA-based companion diagnostic used to identify patients whose tumors carry a BRAF mutation, was simultaneously approved in the United States.15 Vemurafenib’s approval was based on positive results from an interim analysis of BRIM3, a global, randomized, open-label, controlled phase 3 study. This trial compared vemurafenib given orally twice daily with dacarbazine given intravenously (IV) in 675 patients with previously untreated BRAF V600E mutation-positive, unresectable or metastatic melanoma.16 Interim analysis showed that 6-month overall survival (OS) was improved for patients who received vemurafenib relative to those who received dacarbazine: 84% versus 64%, respectively. Median progression-free survival (PFS) was 5.3 months for patients who received vemurafenib compared with 1.6 months for those who received dacarbazine (hazard ratio [HR] 0.26; p<.0001).16 Adverse events (AEs) in the vemurafenib group included cutaneous events, arthralgia, and fatigue. Photosensitivity skin reactions of grade 2 or 3 were seen in 12% of the patients. Grade 3 photosensitivity reactions, which were characterized by blistering, were successfully prevented with sunblock. AEs led to dose modification or interruption in 38% of patients in the vemurafenib group and in 16% of patients in the dacarbazine group. Cutaneous squamous cell carcinoma (SCC), keratoacanthoma, or both developed in 18% of patients receiving vemurafenib. All lesions were treated by simple excision without the need for dose modification of vemurafenib. No other secondary neoplasias were observed in vemurafenib recipients.16 In June 2012, updated results from the BRIM3 study were reported at the 48th Annual American Society of Clinical Oncology (ASCO) Meeting.17 In this analysis, which included patient crossover from the dacarbazine arm to the vemurafenib arm, vemurafenib improved OS. In patients censored at crossover, OS was 13.6 months for vemurafenib and 9.7 months for dacarbazine (HR 0.76; P<.001 post hoc). Vemurafenib also improved PFS; median PFS was 6.9 months in the vemurafenib arm versus 1.6 months in the dacarbazine arm (HR 0.38; P<.001 log-rank post hoc).17 Selected AEs that occurred more frequently in the vemurafenib group included cutaneous SCC, keratoacanthoma, and skin papilloma. Eight patients in the vemurafenib group reported new primary melanomas.17
DabrafenibThe second BRAF inhibitor authorized for marketing in the United States, dabrafenib (Tafinlar), is a reversible kinase inhibitor of V600E-mutant BRAF. Approved by the FDA in May 2013, dabrafenib is indicated for patients with advanced melanoma that contains the V600E mutation of BRAF.5 Concurrent with this approval, the FDA approved the THxID BRAF assay for detection of BRAF V600E mutations. In the drug’s pivotal phase 3 trial, known as BREAK-3, 250 patients with unresectable stage III or stage IV melanoma and a documented BRAF V600E mutation were randomly assigned to dabrafenib given orally twice daily or dacarbazine given intravenously in a 3:1 ratio, respectively.18 The primary end point of the trial was PFS as determined by investigators. (PFS was independently reviewed as a secondary trial end point.) Patients in BREAK-3 were allowed to cross over to the alternative treatment upon development of progressive disease. The study demonstrated that dabrafenib significantly increased median PFS compared with dacarbazine: 5.1 months versus 2.7 months, respectively (HR 0.33; 95% confidence interval [CI], 0.20-0.54). Independent review of the data found that median PFS findings were similarly improved with dabrafenib relative to dacarbazine: 6.7 months versus 2.9 months, respectively (HR 0.35; 95% CI, 0.20-0.61).18 Treatment-related AEs (grade 2 or higher) occurred in 53% of the patients who received dabrafenib and 44% of the patients receiving dacarbazine. The most common AEs with dabrafenib were skin-related toxic effects, fever, fatigue, arthralgia, and headache. Grade 3 or 4 AEs were uncommon in both groups.18 Updated OS data from the BREAK-3 study were presented during the June 2013 ASCO meeting.19 With a median follow-up of 15.2 months and 12.7 months for the 2 groups, OS favored patients treated with dabrafenib (18.2 months vs 15.6 months; HR 0.76; 95% CI, 0.48-1.21), but the difference was not statistically significant. Because more than half (57%) of the patients originally treated with dacarbazine had crossed over to dabrafenib, the OS benefit from initial dabrafenib therapy was likely obscured.19 The updated safety profile of dabrafenib did not change significantly relative to the initial data analysis. The most common AEs in the dabrafenib arm were hyperkeratosis, headache, arthralgia, and pyrexia. Serious AEs occurring in 5% or more of patients on the dabrafenib arm included cutaneous SCC/keratoacanthoma (10%) and pyrexia (5%).18
TrametinibThe first MEK inhibitor approved in the United States, trametinib (Mekinist), is indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test. Concurrent with this May 2013 approval, the FDA approved the THxID BRAF assay for detection of BRAF V600E and V600K mutations. Trametinib is not indicated for the treatment of patients who have received prior BRAF inhibitor therapy.6 Trametinib’s approval was based on the demonstration of an improved PFS in METRIC, a phase 3, international, open-label, randomized, active-controlled trial that enrolled 322 patients with histologically confirmed stage IIIc or IV melanoma.6,23 Patients were determined to be BRAF V600E or V600K mutation–positive based on centralized testing. No more than 1 prior chemotherapy regimen for advanced or metastatic disease was permitted, and patients with prior exposure to BRAF inhibitors or MEK inhibitors were ineligible for the trial. Patients in the METRIC trial were randomized to receive trametinib given orally once daily or chemotherapy, either dacarbazine or paclitaxel given intravenously every 3 weeks. Upon disease progression, patients who were randomized to chemotherapy could cross over to trametinib.23 Both PFS, the study’s primary end point, and OS, a secondary end point, were significantly improved with trametinib. Investigators reported a statistically significant increase in PFS in patients treated with trametinib compared with chemotherapy (HR 0.45; 95% CI, 0.33-0.63; P<.001). The median PFS was 4.8 months for patients taking trametinib (95% CI, 4.3-4.9) compared with 1.5 months for chemotherapy (95% CI, 1.4-2.7). In the trametinib group, the 6-month OS rate was 81%, compared with 67% in the chemotherapy group, a significant difference despite crossover (HR 0.54; 95% CI, 0.32-0.92; P=.01). (At the time of disease progression, almost half [47%] of patients receiving chemotherapy crossed over to receive trametinib.23) Rash, diarrhea, peripheral edema, and fatigue were the most common AEs in the trametinib group. These were managed with dose interruption and dose reduction. Asymptomatic and reversible reductions in cardiac ejection fraction, as well as ocular events, occurred infrequently in the METRIC study. No secondary skin neoplasms were observed.23 Both dabrafenib and trametinib are currently FDA approved as monotherapy, not in combination with each other or with other melanoma therapies.5,6 However, trametinib and dabrafenib have been combined in clinical trials in an effort to delay development of treatment resistance, and to minimize toxicities associated with BRAF inhibition.23 Several phase 3 trials of dabrafenib and trametinib (DT) are currently under way. One of these trials, known as COMBI-AD, is evaluating the efficacy of DT relative to placebo in the adjuvant treatment of high-risk patients with BRAF V600 melanoma.24 A second phase 3 trial compares DT with single-agent vemurafenib in unresectable or metastatic melanoma with BRAF V600E or V600K mutations (COMBI-v).25 What are the next steps in BRAF science and drug development? Use of BRAF inhibitors is now a standard option in BRAF-mutated metastatic melanoma. The successful development of vemurafenib and dabrafenib has been described as a milestone in the care of patients with this deadly disease.26 However, treatment resistance to BRAF inhibition as well as unique toxicities (ie, cutaneous SCCs) and secondary premalignancies and malignancies, have emerged.27,28 Despite impressive initial responses to BRAF inhibitors, it is now known that BRAF-mutated tumor cells eventually develop resistance. This is likely due to the activation of various alternative signaling pathways that can perpetuate cell growth and survival.7 In 2013, researchers reported that BRAF-positive metastatic melanomas develop resistance to drugs that target BRAF and MEK pathways by altering their metabolism.27 By switching to a process known as oxidative phosphorylation to supply energy, tumor cells enhance their ability to survive despite BRAF inhibitor treatment.27 Combination use of BRAF inhibitors and mitochondrial inhibitors is being explored as an effective strategy to improve the long-term efficacy of BRAF inhibitors.27 The mechanisms underlying development of secondary tumors in patients receiving BRAF inhibitors are yet unclear. Some have hypothesized a paradoxical activation of the MEK pathway.28 Although it appears that combination use of BRAF and MEK inhibitors delays the onset of treatment-induced SCCs, it is not yet known whether combination treatment will mitigate emergence of all BRAF-inhibitor–driven pathologies.28 Research is ongoing to better understand and address these limiting features of BRAF inhibitors. To overcome shortcomings associated with current BRAF inhibitors, researchers are also identifying and developing novel BRAF inhibitors. At least 4 other BRAF inhibitors, including BMS-908662, RAF265, LGX818, and PLX3603 (RO5212054), are in early stages development for melanoma and other solid tumors. Examples of ongoing clinical trials that include these agents are provided in Table 2.7,29-33 Since their introduction, BRAF inhibitors have transformed oncologists’ management of metastatic melanoma in patients who have a BRAF mutation. Only a handful of years ago, such patients were expected to live approximately 6 to 9 months from the time of diagnosis.34 Building upon knowledge of RAF kinases, BRAF mutations, and the effects of BRAF on MEKERK signaling, scientists are now exploring novel combinations such as BRAF inhibitors plus MEK inhibitors, immunotherapies, or mitochondrial inhibitors, in the hope that the number and variety of safe and effective treatments for patients with metastatic melanoma and other solid tumors will continue to expand.
- Sharma A, Trivedi NR, Zimmerman MA, et al. Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. Cancer Res. 2005;65:2412-2421.
- Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949-954.
- Bollag G, Tsai J, Zhang J, et al. Vemurafenib: the first drug approved for BRAF-mutant cancer. Nat Rev Drug Discov. 2012;11:873-886.
- Zelboraf [package insert]. South San Francisco, CA: Genentech USA, Inc; 2013.
- Tafinlar [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2013.
- Mekinist [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2013.
- Morris V, Kopetz S. BRAF inhibitors in clinical oncology. F1000Prime Rep. 2013;5:1-6.
- Wong KK. Recent developments in anti-cancer agents targeting the Ras/Raf/MEK/ERK pathway. Recent Pat Anticancer Drug Discov. 2009;4:28-35.
- Wan PT, Garnett MJ, Roe SM, et al. Mechanisms of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell. 2004; 116:855-867.
- McCubrey JA, Steelman LS, Abrams SL, et al. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul. 2006;46:249-279.
- Ascierto PA, Kirkwood JM, Grob JJ, et al. The role of BRAF V600 mutation in melanoma. J Transl Med. 2012;10:85.
- Niault TS, Baccarini M. Targets of Raf in tumorigenesis. Carcinogenesis. 2010;31:1165-1174.
- Long GV, Menzies AM, Nagrial AM, et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol. 2011;29:1239-1246.
- ClinicalTrials.gov Web site. http://clinicaltrials.gov/. Accessed July 12, 2013.
- Press release, August 17, 2011. FDA approves Zelboraf and companion diagnostic test for late-stage skin cancer. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm268241.htm. Accessed July 12, 2013.
- Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011; 364:2507-2516.
- Chapman PB, Hauschild A, Robert C, et al. Updated overall survival (OS) results for BRIM-3, a phase 3 randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAF V600E-mutated melanoma. J Clin Oncol. 2012;30(suppl). Abstract 8502.
- Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380:358-365.
- Hauschild A, Grob JJ, Demidov LV, et al. An update on BREAK-3, a phase 3, randomized trial: dabrafenib versus dacarbazine in patients with BRAF V600E-positive mutation metastatic melanoma. J Clin Oncol. 2013;30(suppl). Abstract 9013.
- ClinicalTrials.gov Web site. A study of RO5185426 (vemurafenib) in patients with metastatic or unresectable papillary thyroid cancer positive for the BRAF V600 mutation. http://clinicaltrials.gov/ct2/show/NCT01286753. Accessed July 12, 2013.
- ClinicalTrials.gov Web site. Vemurafenib and panitumumab combination therapy in patients with BRAF V600E mutated metastatic colorectal cancer. http://clinicaltrials.gov/show/NCT01791309. Accessed July 12, 2013.
- ClinicalTrials.gov Web site. A phase II study of the selective BRAF kinase inhibitor GSK2118436 in subjects with advanced non-small cell lung cancer and BRAF mutations. http://clinicaltrials.gov/show/NCT01336634. Accessed July 12, 2013.
- Flaherty KT, Robert C, Hersey P, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012;367:107-114.
- ClinicalTrials.gov Web site. A study of the BRAF inhibitor dabrafenib in combination with the MEK inhibitor trametinib in the adjuvant treatment of high-risk BRAF V600 mutation-positive melanoma after surgical resection. (COMBI-AD). http://clinicaltrials.gov/show/NCT01682083. Accessed July 12, 2013.
- ClinicalTrials.gov Web site. Dabrafenib plus trametinib vs vemurafenib alone in unresectable or metastatic BRAF V600E/K cutaneous melanoma (COMBI-v). http://clinicaltrials.gov/show/NCT01597908. Accessed July 12, 2013.
- Salama AK, Flaherty KT. BRAF in melanoma: current strategies and future directions. Clin Cancer Res. 2013 Jun 14. [Epub ahead of print]. http://www.ncbi.nlm.nih.gov/pubmed/?term=10.1158%2F1078-0432.CCR-13-0779.
- Haq R, Shoag J, Andreu-Perez P, et al. Oncogenic BRAF regulates oxidative metabolism via PGC1α and MITF. Cancer Cell. 2013;23:302-315.
- Gibney GT, Messina JL, Fedorenko IV, et al. Paradoxical oncogenesis—the long-term effects of BRAF inhibition in melanoma. Nat Rev Clin Oncol. 2013;10:390-399.
- ClinicalTrials.gov Web site. Safety and efficacy study of BMS-908662 in combination with ipilimumab in subjects with advanced melanoma. http://clinicaltrials.gov/show/NCT01245556. Accessed July 12, 2013.
- ClinicalTrials.gov Web site. A phase lb/II multi-center, open-label, dose escalation study of LGX818 and cetuximab or LGX818, BYL719, and cetuximab in patients with BRAF mutant metastatic colorectal cancer. http://clinicaltrials.gov/show/NCT01719380. Accessed July 12, 2013.
- ClinicalTrials.gov Web site. A phase I study of oral LGX818 in adult patients with advanced or metastatic BRAF mutant melanoma. http://clinicaltrials.gov/show/NCT01436656. Accessed July 12, 2013.
- ClinicalTrials.gov Web site. MEK162 and RAF265 in adult patients with advanced solid tumors harboring RAS or BRAFV600E mutations. http://clinicaltrials.gov/show/NCT01352273. Accessed July 12, 2013.
- ClinicalTrials.gov Web site. A study of RO5212054 (PLX3603) in patients with BRAF V600-mutated advanced solid tumours. http://clinicaltrials.gov/show/NCT01143753. Acessed July 12, 2013.
- Gogas HJ, Kirkwood JM, Sondak VK. Chemotherapy for metastatic melanoma: time for a change? Cancer. 2007;109:455-464.
Intratumoral Administration of INT230-6 Improves Drug Diffusion and Uptake into Cancer Cells in Patients with Advanced Solid Tumors
A novel intratumoral chemotherapy agent delivered by direct injection permits the dispersion of cytotoxic drugs into cancer cells to eradicate tumors, according to data from a phase 1/2 trial of INT230-6 alone and in combination with pembrolizumab in patients with advanced solid tumors.
Moving combination immunotherapy into the neoadjuvant setting for patients with stage III melanoma induces a higher rate of pathologic response than adjuvant therapy, said Christian U. Blank, MD, PhD, Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, at the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium.